Compare $ACUT vs $INTI | Chartloom

Compare

$ACUT vs $INTI

Accustem Sciences Inc · Inhibitor Therapeutics Inc

ACUT

Accustem Sciences Inc

INTI

Inhibitor Therapeutics Inc

Compare $ACUT vs $INTI

Comparing Accustem Sciences Inc and Inhibitor Therapeutics Inc

ACUTAccustem Sciences Inc

INTIInhibitor Therapeutics Inc

ACUTAccustem Sciences Inc

Market cap

$2M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-75.6%

52W performance

-67.3%

FCF yield

-50.9%

INTIInhibitor Therapeutics Inc

Market cap

$17M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

108.5%

52W performance

127.9%

FCF yield

-19.1%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ACUT

INTI

Detailed metrics comparison

ACUT

Accustem Sciences Inc

INTI

Inhibitor Therapeutics Inc

Market Cap

ACUT$2M

INTI$17M

Enterprise Value

ACUT$2M

INTI$16M

Price

ACUT$0.15

INTI$0.10

P/E Ratio

ACUTN/A

INTIN/A

P/S Ratio

ACUT0.00x

INTI4.25x

EV/Sales

ACUT0.00x

INTI4.12x

EV/EBITDA

ACUT0.00x

INTI1.61x

P/B Ratio

ACUT2.97x

INTI4,922.43x

P/FCF Ratio

ACUTN/A

INTIN/A

EV/FCF

ACUT-2.01x

INTI-5.09x

PEG Ratio

ACUTN/A

INTIN/A

Forward P/E (NTM)

ACUTN/A

INTIN/A

Forward P/S (NTM)

ACUTN/A

INTIN/A

Revenue (TTM)

ACUT$0

INTI$0

Revenue Growth (YoY)

ACUTN/A

INTIN/A

Forward Rev Growth

ACUT0.0%

INTI0.0%

Gross Margin (TTM)

ACUT0.0%

INTI20.9%

Operating Margin (TTM)

ACUT0.0%

INTI0.0%

EBITDA Margin (TTM)

ACUT0.0%

INTI0.0%

Net Margin (TTM)

ACUT0.0%

INTI0.0%

FCF Margin (TTM)

ACUTN/A

INTIN/A

Net Income (TTM)

ACUT$-2M

INTI$-3M

FCF (TTM)

ACUT$-1M

INTI$-3M

EPS (TTM)

ACUT-$0.10

INTI$0.00

ROE (TTM)

ACUT-21712.9%

INTI-33792.0%

ROA (TTM)

ACUT-10530.0%

INTI-12210.0%

ROIC (TTM)

ACUT-179413.5%

INTI-33792.0%

Cash

ACUT$13K

INTI$516K

Debt

ACUT$63K

INTI$0

Net Cash/Debt

ACUT$-50K

INTI$516K

Current Ratio (TTM)

ACUT0.02x

INTI3.36x

Quick Ratio (TTM)

ACUT0.00x

INTI2.95x

Debt/Equity (TTM)

ACUT0.27x

INTI0.00x

Debt/Assets (TTM)

ACUT0.0%

INTI0.0%

Interest Coverage (TTM)

ACUTN/A

INTIN/A

Net Debt/EBITDA (TTM)

ACUT0.00x

INTI0.00x

Beta

ACUT1.88

INTI-0.79

52W Performance

ACUT-67.3%

INTI127.9%

YTD Performance

ACUT-75.6%

INTI108.5%

% from 52W High

ACUT-93.7%

INTI-21.0%

% from 52W Low

ACUT26.0%

INTI180.0%

Asset Turnover (TTM)

ACUT0.00x

INTI0.50x

FCF Yield (TTM)

ACUT-50.9%

INTI-19.1%

Earnings Yield (TTM)

ACUT-69.8%

INTI-15.9%

Dividend Yield (TTM)

ACUTN/A

INTIN/A

Rule of 40

ACUT0.0

INTI0.0

EV/GP/RG

ACUTN/A

INTIN/A

Ticker research

View ACUT research View INTI research

Metric	ACUT Accustem Sciences Inc	INTI Inhibitor Therapeutics Inc
Market & Valuation
Market Cap	$2M	$17M
Enterprise Value	$2M	$16M
Price	$0.15	$0.10
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	4.25x
EV/Sales	0.00x	4.12x
EV/EBITDA	0.00x	1.61x
P/B Ratio	2.97x	4,922.43x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.01x	-5.09x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	0.0%
Profitability
Gross Margin (TTM)	0.0%	20.9%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-2M	$-3M
FCF (TTM)	$-1M	$-3M
EPS (TTM)	-$0.10	$0.00
ROE (TTM)	-21712.9%	-33792.0%
ROA (TTM)	-10530.0%	-12210.0%
ROIC (TTM)	-179413.5%	-33792.0%
Financial Health
Cash	$13K	$516K
Debt	$63K	$0
Net Cash/Debt	$-50K	$516K
Current Ratio (TTM)	0.02x	3.36x
Quick Ratio (TTM)	0.00x	2.95x
Debt/Equity (TTM)	0.27x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.88	-0.79
52W Performance	-67.3%	127.9%
YTD Performance	-75.6%	108.5%
% from 52W High	-93.7%	-21.0%
% from 52W Low	26.0%	180.0%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.50x
FCF Yield (TTM)	-50.9%	-19.1%
Earnings Yield (TTM)	-69.8%	-15.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ACUT research	View INTI research

Valuation

P/S Ratio

ACUT

0.00x

INTI

4.25x

EV/FCF

INTI

-5.09x

ACUT

-2.01x

Growth & revenue

Forward Revenue Growth

ACUT

0.0%

INTI

0.0%

Profitability & performance

Gross Margin

INTI

20.9%

ACUT

0.0%

ROE

ACUT

-21712.9%

INTI

-33792.0%

FCF Yield %

INTI

-19.1%

ACUT

-50.9%

52-Week Performance

INTI

127.9%

ACUT

-67.3%

Detailed metrics comparison

ACUT

Accustem Sciences Inc

INTI

Inhibitor Therapeutics Inc

Market Cap

ACUT$2M

INTI$17M

Enterprise Value

ACUT$2M

INTI$16M

Price

ACUT$0.15

INTI$0.10

P/E Ratio

ACUTN/A

INTIN/A

P/S Ratio

ACUT0.00x

INTI4.25x

EV/Sales

ACUT0.00x

INTI4.12x

EV/EBITDA

ACUT0.00x

INTI1.61x

P/B Ratio

ACUT2.97x

INTI4,922.43x

P/FCF Ratio

ACUTN/A

INTIN/A

EV/FCF

ACUT-2.01x

INTI-5.09x

PEG Ratio

ACUTN/A

INTIN/A

Forward P/E (NTM)

ACUTN/A

INTIN/A

Forward P/S (NTM)

ACUTN/A

INTIN/A

Revenue (TTM)

ACUT$0

INTI$0

Revenue Growth (YoY)

ACUTN/A

INTIN/A

Forward Rev Growth

ACUT0.0%

INTI0.0%

Gross Margin (TTM)

ACUT0.0%

INTI20.9%

Operating Margin (TTM)

ACUT0.0%

INTI0.0%

EBITDA Margin (TTM)

ACUT0.0%

INTI0.0%

Net Margin (TTM)

ACUT0.0%

INTI0.0%

FCF Margin (TTM)

ACUTN/A

INTIN/A

Net Income (TTM)

ACUT$-2M

INTI$-3M

FCF (TTM)

ACUT$-1M

INTI$-3M

EPS (TTM)

ACUT-$0.10

INTI$0.00

ROE (TTM)

ACUT-21712.9%

INTI-33792.0%

ROA (TTM)

ACUT-10530.0%

INTI-12210.0%

ROIC (TTM)

ACUT-179413.5%

INTI-33792.0%

Cash

ACUT$13K

INTI$516K

Debt

ACUT$63K

INTI$0

Net Cash/Debt

ACUT$-50K

INTI$516K

Current Ratio (TTM)

ACUT0.02x

INTI3.36x

Quick Ratio (TTM)

ACUT0.00x

INTI2.95x

Debt/Equity (TTM)

ACUT0.27x

INTI0.00x

Debt/Assets (TTM)

ACUT0.0%

INTI0.0%

Interest Coverage (TTM)

ACUTN/A

INTIN/A

Net Debt/EBITDA (TTM)

ACUT0.00x

INTI0.00x

Beta

ACUT1.88

INTI-0.79

52W Performance

ACUT-67.3%

INTI127.9%

YTD Performance

ACUT-75.6%

INTI108.5%

% from 52W High

ACUT-93.7%

INTI-21.0%

% from 52W Low

ACUT26.0%

INTI180.0%

Asset Turnover (TTM)

ACUT0.00x

INTI0.50x

FCF Yield (TTM)

ACUT-50.9%

INTI-19.1%

Earnings Yield (TTM)

ACUT-69.8%

INTI-15.9%

Dividend Yield (TTM)

ACUTN/A

INTIN/A

Rule of 40

ACUT0.0

INTI0.0

EV/GP/RG

ACUTN/A

INTIN/A

Ticker research

View ACUT research View INTI research

Metric	ACUT Accustem Sciences Inc	INTI Inhibitor Therapeutics Inc
Market & Valuation
Market Cap	$2M	$17M
Enterprise Value	$2M	$16M
Price	$0.15	$0.10
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	4.25x
EV/Sales	0.00x	4.12x
EV/EBITDA	0.00x	1.61x
P/B Ratio	2.97x	4,922.43x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.01x	-5.09x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	0.0%
Profitability
Gross Margin (TTM)	0.0%	20.9%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-2M	$-3M
FCF (TTM)	$-1M	$-3M
EPS (TTM)	-$0.10	$0.00
ROE (TTM)	-21712.9%	-33792.0%
ROA (TTM)	-10530.0%	-12210.0%
ROIC (TTM)	-179413.5%	-33792.0%
Financial Health
Cash	$13K	$516K
Debt	$63K	$0
Net Cash/Debt	$-50K	$516K
Current Ratio (TTM)	0.02x	3.36x
Quick Ratio (TTM)	0.00x	2.95x
Debt/Equity (TTM)	0.27x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.88	-0.79
52W Performance	-67.3%	127.9%
YTD Performance	-75.6%	108.5%
% from 52W High	-93.7%	-21.0%
% from 52W Low	26.0%	180.0%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.50x
FCF Yield (TTM)	-50.9%	-19.1%
Earnings Yield (TTM)	-69.8%	-15.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ACUT research	View INTI research